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Percutaneous treatment of inter-atrial septal defects has undergone exponential growth in the past 2 decades.
Improved percutaneous devices and interventional techniques with low complication rates make this procedure
an attractive therapeutic option for congenital atrial septal defects (ASD). Although indications for catheter-
based ASD closure are well-documented, those for catheter-based patent foramen ovale (PFO) closure are still
evolving. Results from 2 randomized clinical trials question the benefit of percutaneous PFO closure, but concern
has also been raised about the efficacy of the device used in those trials. This review will focus on the anatomy,
associated syndromes, detection, and data for percutaneous closure of both PFOs and ASDs. (J Am Coll
Cardiol 2012;60:1722–32) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.086p
s
PPercutaneous treatment of inter-atrial septal defects has
opened new areas of research, because unexpected associa-
tions have been uncovered. Improved devices, interventional
techniques, and low complication rates make this procedure
an attractive therapeutic option for congenital atrial septal
defects (ASD). In the United States, the rates of annual
percutaneous patent foramen ovale (PFO) and ASD clo-
sures have increased nearly 50-fold over the past decade.
Although indications for catheter-based ASD closures are
well-documented by many society guidelines, those for
catheter-based PFO closure are still evolving. The results of
2 recent randomized clinical trials raise questions about the
utility of percutaneous PFO closure. This review will focus
on the anatomy, physiology, associated syndromes, detec-
tion, and data for percutaneous closure of both PFOs and
ASDs.
Patent Foramen Ovale
PFO anatomy. The fetus depends upon oxygen that is
transferred in utero from the maternal circulation across the
placenta. Because the fetal lungs are not capable of oxygen-
ating blood, the immature lungs are bypassed via a commu-
nication between the atria at the foramen ovale. Oxygenated
blood is directed from the inferior vena cava to the superior
aspect of the right atrium (RA) via the Eustachian valve, then
crosses the foramen ovale into the left atrium (LA) and enters
the systemic circulation (Fig. 1, Online Videos 1 and 2).
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RESPECT and REDUCE trials. Dr. Shenoda has reported that he has no
relationships relevant to the contents of this paper to disclose.Manuscript received September 13, 2011; revised manuscript received January 20,
2012, accepted January 25, 2012.At the time of birth, right heart filling pressures and
pulmonary vascular resistance decrease, leading to higher
LA pressures, and closure of the foramen ovale flap against
the septum secundum. The contact between the septum
primum flap and the septum secundum leads to fusion of
these tissues and permanent closure of the foramen ovale, a
process that is usually completed within the first year of life.
The foramen ovale flap fails to fuse in approximately 20% of
humans, which leads to persistent patency. Because PFOs
aggregate in families, it is hypothesized that closure of the
PFO is in part determined by genes such as Notch 3, which
is associated with embryologic control of the septum and is
deficient in the cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL)
syndrome in which there is a high frequency of PFO,
migraine, and leukoencephalopathy.
Physiology of right-to-left shunting through a PFO. In
the basal state, the LA pressure is higher than RA pressure,
so the septum primum flap of the PFO is pressed against the
septum secundum, which keeps the foramen ovale closed.
However, if the RA pressure exceeds the LA pressure, blood
can then flow from the RA to the LA. This occurs
frequently when a person coughs, laughs, sneezes, takes a
deep breath, or upon release of the Valsalva maneuver,
which increases the return of venous blood to the RA
(Fig. 2, Online Videos 3 and 4). Approximately 5% of
atients with stroke or migraine have a history of vigorous
training or exercising immediately before their event.
FO associated syndromes. CRYPTOGENIC STROKE.
Paradoxical embolism through a PFO was first described in
1877 by Julius Cohnheim during an autopsy of a young
woman with a fatal occlusion of a cerebral artery. He
observed that the patient had a significant lower extremity
thrombus and a large PFO, which he hypothesized served as
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October 30, 2012:1722–32 Percutaneous Treatment of PFO and ASDa conduit for an arterial embolism that paradoxically started in
the venous circulation. The advent of echocardiography im-
proved the understanding of PFO anatomy and detection.
In 1988, several observational studies emphasized the asso-
ciation of a PFO with cryptogenic stroke (where there is no
identifiable cause for the stroke) in young patients (1,2).
With contrast echocardiography, the prevalence of a PFO in
patients under the age of 55 with cryptogenic stroke was
54% (1). Other studies consistently corroborate the associ-
ation of PFO and cryptogenic stroke even in older patients
with stroke of unknown etiology (3,4). There are approxi-
mately 140,000 cryptogenic strokes/year in the United
States, and 50% of them have a PFO, so it is estimated that
the risk of developing a stroke in someone with a PFO is 1
in 1,000/year. The recurrence rate in patients with a PFO
who have already suffered a stroke is approximately 2%
annually. Higher stroke rates (15%) have been associated
with the presence of an atrial septal aneurysm (ASA). The
mechanism for the increased risk of paradoxical embolism in
patients with an ASA and PFO was initially thought to be
due to thrombus formation on the redundant interatrial
tissue, but this has not been documented, despite intensive
investigation with transesophageal echocardiography
(TEE). The current theory is that an ASA permits greater
flow and therefore increases the chance of a thrombus
passing from the venous to the arterial circulation (5–7).
Although it is logical to assume that larger PFOs would
be associated with an increased frequency of cryptogenic
stroke or a larger stroke burden, the data have been
conflicting. There is a loose correlation between stroke
volume on magnetic resonance imaging and PFO size on
cardiac echocardiography, but there is wide overlap, and it is
possible for a large stroke to occur with a small PFO (8).
Thus, PFO size and anatomy should not be the criteria to
determine whether a PFO should be closed.
Venous thrombosis is believed to be the source of
paradoxical embolism in cryptogenic strokes associated with
PFOs. However, the incidence of detectable veno-occlusive
disease in the lower extremities and pelvis is low. Magnetic
resonance imaging venograms in patients with cryptogenic
stroke demonstrate a higher incidence of pelvic thrombosis
compared with patients with strokes of identifiable causes
(20% vs. 4%, p  0.03) (9). Small emboli might be shed
rom small varicose veins or hemorrhoids and might not be
etected by current imaging modalities.
Observational studies suggest that medical treatment
ith antiplatelet or antithrombotic agents lowers recurrent
vent rates. However, in the WARSS study (Warfarin
spirin Recurrent Stroke Study), there was no difference in
he recurrence rate of stroke in patients who were taking
arfarin or aspirin, but the recurrence rate was high in both
roups at 8%/year (10). A substudy of this trial assessed the
ecurrence rate in patients who had TEEs (PICSS [Patent
oramen Ovale in Cryptogenic Stroke Study]) (11). The
ecurrence rate at 2 years was 2.7 times higher in patients
65 years of age who had a PFO (38%), compared with rhose people with cryptogenic
troke who did not have a PFO
14%).
STUDIES OF PFO CLOSURE FOR
CRYPTOGENIC STROKE. As dis-
inguished from medical therapy,
urgical closure of PFO in 193
atients with cryptogenic stroke
howed a recurrent annual stroke
isk of only 0.42% and transient
schemic attack (TIA) risk of
.56%. A pooled analysis of 24
tudies comprising 3,819 patients
ho had percutaneous PFO clo-
ure suggests a recurrent annual
troke risk of 0.47% and recur-
ent TIA risk of 0.85%. On the
asis of these observations, it was
redicted that a randomized trial
ould prove that PFO closure
as preferable to medical therapy
o prevent recurrent cryptogenic
troke.
The CLOSURE I trial (Eval-
ation of the STARFlex Septal
losure System in Patients With
Stroke or TIA Due to the
ossible Passage of a Clot of
nknown Origin Through a
atent Foramen Ovale [PFO])
as the first randomized clinical
rial evaluating the effects of PFO closure on recurrent
ryptogenic stroke and TIA versus medical therapy. This
as a superiority trial that randomized 909 patients with a
istory of cryptogenic stroke to percutaneous PFO closure
ith a STARFlex PFO device versus medical therapy with
arfarin (international normalized ratio goal 2.0 to 3.0),
spirin 325 mg alone, or aspirin 81 mg plus warfarin. The
esults did not demonstrate a benefit of PFO closure with
he STARFlex device compared with medical therapy. The
rimary composite endpoint of a reduction in stroke, TIA,
nd mortality at 2 years was reached in 5.9% of patients in
he device arm and 7.7% of patients in the medical treat-
ent arm (p  0.30). Individually, stroke (3.1% vs. 3.4.%)
r TIA (3.3% vs. 4.6%) was not statistically different
etween the 2 treatment arms. Device closure was success-
ul in only 87% of cases, which is similar to previous
evice closure studies with the STARFlex device but lower
han that reported for other PFO closure devices. Major
ascular complications (3.2%) and atrial fibrillation (5.7%)
ere significantly higher in the device group (p  0.001 for
oth).
There are several potential explanations for this contra-
iction between the observational reports and this first
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
ASA  atrial septal
aneurysm
ASD  atrial septal defect
ASO  Amplatzer Septal
Occluder
BCP  birth control pills
FDA  Food and Drug
Administration
HSO  Helex Septal
Occluder
LA  left atrium/atrial
MI  myocardial infarction
OSA  obstructive sleep
apnea
PFO  patent foramen
ovale
RA  right atrium/atrial
TEE  transesophageal
echocardiogram
TIA  transient ischemic
attack
TTE  transthoracic
echocardiogram
WML  white matter lesionandomized clinical trial of PFO closure for cryptogenic
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thrombus formation on this device and the high incidence
of large residual shunts with the CardioSEAL-STARFlex
(NMT Medical, Inc., Boston, Massachusetts) devices com-
pared with other products (12). In a randomized trial
comparing 3 transcatheter PFO devices (CardioSEAL-
STARFlex occluder, Amplatzer PFO/ASD occluder [St.
Jude Medical, Plymouth, Minnesota], and Gore Helex
occluder [W. L. Gore & Associates, Inc., Flagstaff, Ari-
zona]), the STARFlex device had a 3.6% incidence of
thrombus formation at 30-day follow-up, compared with
0% for the other 2 devices (13). Procedural complications
have also been significantly higher for the STARFlex
device, including a higher rate of peri-procedural atrial
fibrillation (5% vs. 1.1%). There is also a high rate of large
esidual shunt (13%) with this device. These negative
spects of the STARFlex device might have contributed
o the higher-than-expected recurrent stroke rate in the
LOSURE I trial.
There are 2 current randomized clinical trials for crypto-
enic stroke, including the REDUCE trial with the Gore
elex Septal Occluder and the RESPECT trial (Random-
zed Evaluation of Recurrent Stroke Comparing PFO
losure to Established Current Standard of Care Treat-
ent) with the Amplatzer PFO occluder device. The
ESPECT trial has just been completed, and the results are
ikely to be announced after publication of this review. It has
een difficult to conduct these randomized trials for cryp-
Figure 1 Fossa Ovale Anatomy
The fossa ovalis is bordered by the septum secundum superiorly and the
septum primum inferiorly. See Online Videos 1 and 2.ogenic stroke. Event rates for recurrent strokes are low,approximately 2%/year. Thus, to adequately power a study
with clinically significant endpoints requires a large number
of patients and long-term follow-up (5 years). In addition,
these trials are taking place in an unusual environment for
new device technology. When a new device is developed, it
usually is not available to the public unless they participate
in a randomized trial. However, the U.S. Food and Drug
Administration (FDA) has approved several devices for
closure of ASDs that can be used effectively to close a PFO
off-label. Many patients and referring physicians prefer to
have the PFO closed definitively rather than participate in a
randomized trial in which there is a 50% chance of receiving
medical therapy. Even though there is no scientific proof
that PFO closure is preferable to medical treatment, pa-
tients who have had a stroke are anxious that they will suffer
another event and often prefer the certainty of an interven-
tion over medical therapy. This is especially ironic, because
the initial results of the CLOSURE I trial suggest that there
is equality in distribution between these 2 treatment op-
tions. These concerns result in a self-selection bias, because
patients at high risk of recurrent stroke are less likely to be
enrolled in the randomized clinical trials. These daunting
problems should be taken into consideration when evaluat-
ing the ultimate results of current PFO stroke trials.
ASSOCIATION OF MIGRAINE HEADACHE AND PFO. The
prevalence of migraine is 18% in women and 6% in men.
The neurobiology of migraine headache disorders has yet to
be fully elucidated. Previous theories with regard to the
etiology of migraines hypothesized that cerebral vasospasm
Figure 2 Lateral Angiogram of a Patent Foramen Ovale
A right atrial angiogram reveals a patent foramen ovale (arrow) with contrast
filling the left atrium. See Online Videos 3 and 4. LA  left atrium; RA  right
atrium; RV  right ventricle, RVOT  right ventricular outflow tract.
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In addition, stroke associated with migraine was believed to
be secondary to such intense arterial constriction that a
cerebral infarction ensued directly from the vasospasm.
Magnetic resonance imaging and positron emission tomog-
raphy have subsequently demonstrated that cerebral vasodi-
lation occurs first, followed by vasoconstriction that is
associated with cortical neuronal depression. This inhibition
of neurons spreads as a wave from the optical cortex to the
motor and sensory cortices, leading to transient neurological
deficits that are identified as migraine auras. This more
recent concept of migraine has been demonstrated in
elegant experiments with a mouse transgenic model of
human genes associated with familial migraine and hemi-
plegia due to abnormalities in calcium or sodium channel
proteins (14).
Given this current concept of migraine physiology, it is
hypothesized that a PFO serves as a conduit for the passage
of chemical triggers that interact with neuronal receptors in
susceptible people. These triggers induce cortical depolar-
ization and concomitant transient neurological deficits,
leading to the clinical phenotype of auras and migraine
headache. The PFO permits the chemical triggers to reach
the brain without entering the pulmonary circulation where
degradation of these products would normally occur. Mi-
graines have also been induced in a mouse model by
injecting particles that embolize to the brain (15).
The initial reports associating migraine headaches with
aura and PFO disclosed a prevalence of right-to-left shunt-
ing by transcranial Doppler of 41% to 48%, compared with
16% to 20% in control subjects (16,17). The association of
PFO closure and the cessation of migraine headaches was
first published in 2000 by Wilmshurst et al. (18) as an
incidental finding while studying the effects of PFO closure
on people with decompression illness. In 37 of these
patients who also had migraine headaches, 45% reported
cessation of their headaches after PFO closure.
In addition to the close association of PFO and migraine
with aura, there is also a higher risk of stroke in patients
with a history of migraine. A meta-analysis of 14 studies
revealed a 2-fold increased risk of ischemic stroke in
migraine patients, compared with people without migraine
(19). Those individuals with associated aura had a relative
risk of 2.27, compared with 1.83 in those without aura. It is
hypothesized that this increased risk of ischemic stroke in
migraineurs is due primarily to the mechanism of paradox-
ical embolism through a PFO. Wilmshurst et al. (20)
documented a high incidence of PFO (84%) in migraineurs
who had suffered a stroke, compared with migraineurs
without a history of stroke (38%). We believe this concept
also explains the 8-fold higher incidence of stroke in
migraineurs who use birth control pills (BCPs) or the
15-fold higher risk in migraineurs who smoke tobacco and
use BCPs. The postulated mechanism is that BCP or
smoking tobacco predisposes to venous thrombus, and the
presence of the migraine identifies those people with a phigher likelihood of having a PFO, so both the thrombus
and the passageway are present in these subsets.
STUDIES OF PFO CLOSURE IN MIGRAINEURS. Over the past
ecade, there have been 17 reported observational studies
valuating the effect of percutaneous PFO closure on
igraine headaches. A pooled analysis of these 866 people
eveals that 83% had either complete cessation of migraines
r a clinically significant reduction (defined as 50%
eduction in headache days/month). The number of patients
uffering from migraine with aura who responded was
pproximately 2-fold greater than those who had migraine
ithout aura.
The only completed randomized trial of PFO closure for
igraine headaches is the MIST (Migraine Intervention
ith STARFlex Technology) Trial. The MIST trial en-
olled 147 patients who were randomized 1:1 to device
losure with the STARFlex septal implant (NMT Medical)
r a sham procedure consisting of a skin incision in the
roin under general anesthesia. Patients averaged 5 migraine
ttacks/month with 30 headache days over a 3-month
eriod. After 6 months, the primary endpoint of complete
essation of migraine headaches after device closure was not
eached, because only 3 patients in each group reported no
urther migraine headaches. The secondary endpoints,
hich included the incidence, frequency, and severity of
igraine attacks were also not met in this trial.
The MIST trial has been extensively critiqued for meth-
dological design and credibility. The patient population
nrolled included those with chronic headaches, a subgroup
hat might not respond to conventional therapies, because
he headache etiology is obscured with over-medication and
rug withdrawal headache. The procedural complications
ere 6.8% in the MIST I trial, which is higher than that
eported in multiple observational studies. The follow-up
eriod of 3 to 6 months might be too brief, because
ercutaneous PFO closure devices might require more time
o endothelialize and eliminate shunting through a PFO.
nly contrast transthoracic echocardiograms (TTEs) were
btained at follow-up, which is less sensitive than TEE or
ranscranial Doppler detection of right-to-left shunting.
here is also significant controversy about the true inci-
ence of residual shunts, which damages the credibility of
he study. Although the MIST I trial reported a 5% residual
hunt in the device arm at 6 months, one of the principle
nvestigators alleges that 35% of device-treated patients had
large residual shunt. Given that there was no independent
chocardiography core laboratory, these allegations are mat-
ers of concern and require cautious interpretation of the
IST trial.
The ongoing PREMIUM Migraine Trial (Prospective,
andomized Investigation to Evaluate Incidence of Head-
che Reduction in Subjects With Migraine and PFO Using
he Amplatzer PFO Occluder to Medical Management)
ight elucidate the role of PFO closure in migraine
atients. This is a randomized, sham-controlled trial eval-
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Percutaneous Treatment of PFO and ASD October 30, 2012:1722–32uating the effectiveness of percutaneous PFO closure with
the Amplatzer PFO Occluder (St. Jude Medical, Plymouth,
Minnesota) versus a sham procedure plus standard medical
therapy. This trial might address the shortcomings of the
MIST I trial by enrolling a more appropriate patient
population (excluding patients with chronic headaches), use
of a more effective closure device with less complications,
and extended follow-up (1 year) with trans-cranial Doppler
and TEE evaluation of the implanted device.
PLATYPNEA-ORTHODEOXIA SYNDROME. Platypnea-
Orthodeoxia is a rare syndrome consisting of hypoxemia
and shortness of breath upon assuming an upright position.
It is believed that anatomic changes with age, such as
uncoiling of the aorta, diaphragmatic paralysis, stretch of
the atrial septum, and increase shunting through a PFO,
produce significant desaturation of arterial blood when the
patient stands up or bends over. Landzberg et al. (21) first
described relief of symptoms and reversal of arterial desatu-
ration in this syndrome after transcatheter closure of PFOs
in 8 patients. More recently, a French registry of 78 patients
reported a significant increase in oxygen saturation and
dyspnea improvement immediately after percutaneous PFO
closure (22).
MYOCARDIAL INFARCTION WITH NORMAL CORONARIES.
The incidence of myocardial infarction (MI) with normal
coronary arteries is reported to be between 1% and 7% of
patients who present with cardiac enzyme documented MI.
A PFO might serve as the passageway for a venous
thrombus that embolizes to a coronary artery. Additionally,
coronary vasospasm might occur from vasoactive substances,
such as serotonin, that could pass unaltered through a PFO
and have a direct effect on the coronary vasculature. This
hypothesis is difficult to prove but should be considered in
the select patient population of young people with an MI
but no atherosclerosis.
DECOMPRESSION SYNDROME. Decompression illness is
aused by nitrogen microbubbles formed in the vasculature
s a result of a reduction in environmental pressure. Symp-
oms are usually constitutional and nonspecific. The rate of
ccurrence has decreased due to improved decompression
rocedures but still affects approximately 1,000 divers/year.
he risk of developing decompression illness is 5- to 13-fold
igher in individuals with a PFO (23,24). Wilmshurst et al.
25,26) first reported a decreased incidence of decompres-
ion syndrome in divers after transcatheter closure of PFOs.
ince then numerous reports have followed, with long-term
revention of this syndrome. No specific guidelines exist for
FO closure in people who have decompression illness, but
he options are to stop diving, decrease the depth or time of
ives, or undergo percutaneous PFO closure.
HIGH ALTITUDE PULMONARY EDEMA. Although the exact
athogenesis of High Altitude Pulmonary Edema has yet to
e clarified, PFO has been implicated as a contributing
actor. Allemann et al. (27) reported a 4-fold increasedrequency of PFO in individuals susceptible to developing
igh altitude pulmonary edema, compared with those who
ere resistant. The degree of arterial hypoxemia correlated
ith PFO size. The proposed patho-physiology entails a
ycle of high altitude hypoxia producing pulmonary vaso-
onstriction and hypertension. In the presence of a PFO,
here is increased right-to-left shunting, leading to worsen-
ng arterial hypoxemia, altered alveolar-arterial gradients,
nd capillary leakage with pulmonary edema. Elimination of
ight-to-left shunting via percutaneous PFO closure has
een reported in anecdotal cases to have benefits (28).
OBSTRUCTIVE SLEEP APNEA EXACERBATION. It is esti-
mated that 5% of U.S. adults are affected by obstructive
sleep apnea (OSA), which is associated with significant
morbidity and has been linked to various cardiovascular
conditions. The prevalence of a PFO in adults with OSA is
significantly higher than the general population and has
been reported to be as high as 69% (29). Those with OSA
and a PFO have significantly lower arterial oxygen satura-
tion after periods of sleep apnea compared with those
without a PFO. It is postulated that the underlying mech-
anism for these observations involves hypoventilation-
induced hypoxic pulmonary vasoconstriction, leading to
elevated right heart filling pressures and increased right-to-
left shunting through the PFO. There are several reports of
significant improvements in symptoms and arterial satura-
tion in OSA patients who have undergone PFO closure
(30,31). Although these initial reports are encouraging, a
randomized trial of PFO closure would be appropriate
before it is recommended to close PFOs in OSA patients.
CEREBRAL WHITE MATTER LESIONS. White matter lesions
(WMLs) are defects of the neuronal axons where myelin is
replaced by central nervous system fluid (Fig. 3). Histolog-
ically, WMLs demonstrate demyelination, axonal loss, and
astrocytic gliosis. Although the pathophysiology of these
brain lesions remains obscure, they have been linked to an
increased stroke risk, personality changes, and dementia
associated with Alzheimer’s disease. Hypotheses with re-
gard to the mechanism of WML formation include focal
cerebral hypoperfusion due to spasm, metabolic imbalances
due to migraines with aura, microvascular ischemic changes,
and/or embolic phenomena from right-to-left shunting
(32). A meta-analysis of 7 studies found a 4-fold increase of
WMLs in migraine patients compared with a control group
(33). Of our patients with PFO without migraine, who also
had magnetic resonance imaging, one-third demonstrated
WMLs. Thus there might be multiple causes of these brain
abnormalities that include metabolic and embolic pathways.
PFO detection. Contrast TTE is usually the initial diag-
nostic modality for the detection of intracardiac shunts.
However, TTE lacks the sensitivity and specificity of TEE,
which has better image resolution, especially of posterior
heart structures such as the interatrial septum. Although a
right-to-left shunt might occur at rest, the detection of
shunting usually requires a Valsalva maneuver, which en-
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Limitations of TEE imaging in the detection of right-to-
left interatrial shunts include operator experience, difficult
imaging planes, and lack of an adequate Valsalva maneuver
because of sedation and the presence of the tube in the
oropharynx. Transcranial Doppler is a noninvasive proce-
dure that detects contrast microbubbles passing through the
middle cerebral artery. Transcranial Doppler has been
reported to have greater sensitivity for the detection of a
PFO compared with TEE. Our center uses transcranial
Doppler as the preferred screening method and TEE or
intracardiac echocardiography to distinguish pulmonary
from intracardiac shunts.
Percutaneous PFO closure complications. Percutaneous
PFO closure is a relatively safe procedure and frequently
is performed on an outpatient basis. Observational stud-
ies of transcatheter PFO closure have reported a major
complication rate between 0.2% and 1.5% (34,35) for
procedural-related death, hemorrhage requiring transfu-
sion, cardiac tamponade, and fatal pulmonary emboli.
Minor complications including peri-procedural atrial ar-
rhythmias, device arm fractures, device embolization,
thrombosis, and femoral hematomas range from 7.9% to
11.5% (34,35). Newer percutaneous devices and smaller
catheters have led to a decrease in reported major and
Figure 3 White Matter Lesion on
Magnetic Resonance Imaging
White matter lesion seen on magnetic resonance imaging (arrow) in a 35 year-old
female with migraines and visual auras. No permanent neurologic deficit.minor complications. eThe incidence of atrial fibrillation after device closure of
a PFO is estimated to be 2.5% annually (36), but this
depends on the device used. The CardioSEAL-STARFlex
device has up to a 7% incidence of post-procedural atrial
tachyarrhythmias. Larger Amplatzer devices (33 mm)
have also been associated with increased rates of post-
procedural atrial fibrillation.
NICKEL ALLERGY AND MIGRAINE HEADACHES AFTER
ATRIAL DEFECT CLOSURE. A transient and paradoxical in-
crease in migraine headaches in a minority of patients
immediately after percutaneous PFO or ASD closure is
well-documented. This has been attributed to enhanced
inflammation induced by the device, especially if the recip-
ient has a nickel allergy (37), which affects 15% of the
general population. A local inflammatory reaction on the
LA side might lead to platelet activation and release of
serotonin or other potential chemical triggers of migraine.
This hypothesis is supported by the observation that clopi-
dogrel or steroids often reduce the post-procedural mi-
graines. In addition, these patients might also experience
chest discomfort and palpitations, presumably due to local
inflammation, nickel sensitivity, or formation of fibrous scar
tissue. These side effects might take 3 to 6 months to resolve
but on occasion might be so severe that the patient requests
removal of the device.
DEVICE EXPLANTATION. Once the device has been in place
or several months, scar tissue forms and surgery is required
o explant the device. A multi-center survey of 13,736
ercutaneous PFO device implants revealed an incidence of
urgical removal of 0.28% (38). Explantation was noted to
e device-specific, because the CardioSEAL device had a 4
o 5 times higher rate of surgical removal compared with
mplatzer and Gore Helex devices. The CardioSEAL
evices were removed primarily due to residual shunts or
hrombus formation.
uture directions. Until randomized clinical trials demon-
trate positive results, the role of PFO closure will remain
ndefined. Even if the stroke trials are inconclusive due to
ifficulty with enrollment, patients who have had a stroke
re likely to continue to want their PFO closed off-label. If
he PREMIUM migraine trial or the RESPECT or
EDUCE stroke trials demonstrate a significant benefit of
FO closure, it could lead to a dramatic rise in the
requency of this intervention. Other conditions that might
e associated with right-to-left shunting through a PFO
ontinue to be investigated, and observations concerning
FO will provide exciting areas of research for years to
ome.
ranscatheter Treatment of ASD
SD introduction. This discussion will be limited to
ecundum ASDs, which are one of the most common forms
f congenital heart disease. The incidence of ASD is
stimated to be 1 in 1,500 live births and accounts for 30%
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Females are affected twice as often as males.
Although the majority of ASDs are sporadic, genetic
syndromes such as Holt-Oram and Ellis van Creveld
suggest that an inheritable component is involved in the
formation of these interatrial defects. Mutations in the
NKX2-5 gene, a cardiac homeobox gene involved in normal
cardiac development, are responsible for an autosomal
dominant familial ASD that is commonly associated with
atrioventricular block (39,40). Sporadic ASDs are also
associated with NKX2-5 gene mutations, although these
ave low penetrance and are not usually associated with
trioventricular block.
SD anatomy. A deficiency of the inter-atrial septal struc-
ure can present in several different forms (Fig. 4). Ostium
ecundum ASDs account for approximately 75% of septal
efects. The majority of secundum ASDs result from
xcessive resorption of the atrial septum primum, resulting
n a deficient or absent fossa ovalis area. Absence or
nderdevelopment of the superior limbus of the septum
ecundum accounts for a minority of ostium secundum
SDs, and is likely the result of a distinctive morphogenetic
rocess. Although the size and shape of secundum ASDs
ary greatly, the vast majority of these defects are amenable
o transcatheter closure. Other types of interatrial defects
uch as ostium primum, sinus venosus, or coronary sinus
efects are usually not amenable to catheter-based closure
Fig. 4).
SD pathophysiology. The degree of interatrial shunting
s dependent upon the compliance of the right and left
entricles, the systemic and pulmonary circulation resis-
ance, and the size of the defect. Larger ASDs lead to nearly
qual RA and LA pressures, and therefore left-to-right
hunting depends on the higher right ventricular compli-
nce compared with the left ventricle. Volume overload of
Figure 4 Types of ASDs
An illustration of the anatomy of atrial septal defects (ASD).
VSD  ventricular septal defect.che right-sided structures leads to dilation of the RA, right
entricle, and pulmonary system. Chronic left-to-right
hunting in adults might lead to mild-to-moderate pulmo-
ary hypertension, the single most influential factor in the
linical course of ASD (41). However, ASDs are not likely
o produce the classic Eisenmenger’s syndrome seen with
entricular septal defect. Cases of severe pulmonary hyper-
ension in ASD patients are possibly due to simultaneous
rimary pulmonary hypertension. In addition, atrial ar-
hythmias, most commonly atrial flutter/fibrillation, occur
ue to chronic right-sided heart volume and pressure
verload.
SD clinical presentation. Approximately 75% of adult
atients with ASD are symptomatic by the fifth decade of
ife, with dyspnea on exertion and fatigue being the most
ommon presenting symptoms. Small ASDs (10 mm)
ay close spontaneously by the age of 10 years. However,
mall ASDs might present later in life due to decreased left
entricular compliance associated with aging. Adults might
lso present with atrial tachyarrhythmias, paradoxical em-
olism, right ventricular failure, platypnea, orthodeoxia, or
ecurrent pulmonary infections.
Atrial flutter and fibrillation are commonly seen in
nrepaired ASD patients. The prevalence of these atrial
rrhythmias increases with age and is seen in up to 22% of
SD patients over the age of 50 years. The likely mecha-
ism for these arrhythmias is stretching of the atrium from
hronic volume overload.
Similar to a PFO, an ASD has an increased risk of
aradoxical embolism, leading to cryptogenic stroke. Al-
hough the predominant inter-atrial shunt in ASD is
eft-to-right, transient elevations in RA pressure can pro-
uce reversal of flow and facilitate paradoxical embolism. The
ncidence of paradoxical embolism is reported as 11% to 14%
n ASD patients referred for percutaneous closure (42).
Atrial septal defect is one of the most common congenital
eart defects found during pregnancy. Pregnant patients
ith an unrepaired ASD suffer a higher risk of pre-
clampsia and fetal mortality when compared with the
eneral population. The pregnant woman with an ASD is
redisposed to paradoxical embolism due to a hypercoagu-
able state and enhanced right-to-left shunting from in-
reased plasma volume and decreased peripheral vascular
esistance. Although percutaneous closure of an ASD dur-
ng pregnancy can be accomplished, it is preferable to close
arge ASDs before pregnancy.
SD detection. Transthoracic echocardiography remains
he primary diagnostic modality for the detection of ASD,
specially in children. In adults, a TEE can identify the
argins of the deficient atrial septum and also assess the
ordering structures (i.e., aorta, superior vena cava/inferior
ena cava, pulmonary veins, atrioventricular valves, and
oronary sinus). Patients with inadequate imaging, ques-
ionable ASD diagnosis, or unexplained RV volume over-
oad, warrant further assessment with TEE. Contrast echo-
ardiography with agitated saline has a limited role in the
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of residual shunts after transcatheter closure. A TEE with
3-dimensional imaging is a newer technique, which im-
proves the visualization of ASDs, their surrounding atrial
rims and structures, and can assist during percutaneous
closure.
ASD indications for closure. The American College of
Cardiology (ACC)/American Heart Association (AHA)
guidelines recommend ASD closure for patients with RA
and right ventricular enlargement, regardless of symptoms
(Class I) (43). Long-term complications occur in up to 10%
of patients with unrepaired ASDs. The age at which an
ASD is repaired is the single most important predictor of
long-term outcomes. In patients undergoing ASD repair
before age 24, long-term survival is similar to age- and
sex-matched control subjects. Patients with ASD surgical
repairs between ages 25 and 41 had a reduced survival after
27-year follow-up, compared with an age- and sex-matched
control group.
The reasons for these survival reductions are not com-
pletely understood. Several theories include irreversible
damage to the right ventricle, age-related increases in
pulmonary hypertension, and a higher incidence of atrial
fibrillation leading to increased strokes (44). The incidence
of atrial arrhythmias and subsequent strokes does not
decrease in patients with ASDs repaired after age 40.
Nonetheless, closure in these individuals is warranted, given
the modest survival benefits, improvement in symptoms,
functional status, and incidence of heart failure.
The ACC/AHA guidelines state that smaller ASDs (a
diameter of 5 mm) with no evidence of right ventricular
enlargement or pulmonary hypertension do not require
closure, because they are not considered significant enough
to affect the clinical course of these individuals. Smaller
ASDs that are associated with paradoxical embolism or
orthodeoxia-platypnea can be closed according to guideline
recommendations (Class IIA).
The only absolute contraindication for ASD closure
pertains to patients with irreversible pulmonary hyperten-
sion (pulmonary vascular resistance 8 Woods units) and
no evidence of left-to-right shunting (Class III). Therefore,
in patients with known pulmonary hypertension, a complete
assessment of reversibility should be performed. Patients
with a pulmonary artery pressure less than two-thirds
systemic pressure, a pulmonary vascular resistance less than
two-thirds of systemic resistance, or a positive response to
pulmonary vasodilator therapy can be considered for ASD
closure.
Percutaneous ASD treatment. Percutaneous closure of an
ASD was pioneered by King and Mills in 1976 (45), but
technology has evolved such that most adult secundum
ASD closures can be performed as an outpatient procedure.
Percutaneous ASD closure has largely replaced surgical
treatment of secundum ASD, except for large defects (38
mm diameter), insufficient septal rims, or insufficient LA
size to accommodate a device. An adequate septal rimrequires 5 mm of septal tissue from the ASD to the superior
and inferior vena cava, right upper and lower pulmonary
veins, coronary sinus, and mitral/tricuspid valves (46). Al-
though a deficient retro-aortic rim (anterior rim) is not a
contraindication to percutaneous device closure, careful
consideration and technique is required for successful device
placement. With experience, operators have been able to
close a range of challenging defects, including defects with
deficient posterior rim, superior vena cava rim, and even
inferior vena cava rims.
A nonrandomized multicenter trial compared percutane-
ous closure of secundum ASD with the Amplatzer Septal
Occluder (ASO) with surgical closure (47). Percutaneous
closure was associated with a significant lower complication
rate (7.2% vs. 24%), hospital stay (1.0 vs. 3.4 days), and
similar efficacy rates (98.5% vs. 100%). A similar nonran-
domized, multicenter trial evaluating the safety and efficacy
of the Helex Septal Occluder (HSO) for secundum ASD
closure used a surgical arm as the control group (48). The
transcatheter Gore-Helex group had less major adverse
events at 12 months (5.9% vs. 10.9%) with comparable
clinical success rates (a composite endpoint of safety and
efficacy of 91.7% vs. 83.7%, p 0.001 for noninferiority). In
addition, percutaneous ASD closure costs less than surgical
repair. The current ACC/AHA Congenital Heart Disease
guidelines do not differentiate between percutaneous and
surgical repair of ASD except for ASDs other than the
secundum type. Thus, percutaneous closure of secundum
ASD is now the preferred method of repair in those patients
with appropriate anatomy.
Percutaneous device options. Although there are 15 de-
vices internationally available for percutaneous secundum
ASD closure, there are only 3 FDA-approved devices in the
United States. The ASO was the first device approved by
the FDA for transcatheter closure of ASD (Fig. 5). Since its
approval in 2001, approximately 46,000 have been im-
planted in the United States, and 200,000 have been
implanted worldwide. The ASO device is composed of a
braided nitinol wire mesh. It is a self-centering, self-
expandable device that is shaped into 2 flat discs with a
connecting waist. Polyester fabric inserts are sewn into the
nitinol wire mesh to promote tissue growth and defect
closure. The ASO device is delivered via a 60- to 80-cm-
length sheath that is 6- to 12-F in diameter, depending on
the device size. The device size is determined by the waist
diameter, which ranges from 4 to 38 mm and corresponds to
the atrial defect diameter. Once the device has been placed,
it can be easily recaptured into the delivery sheath for
re-positioning, as long as the delivery cable has not been
released. The ASO has been the most-used percutaneous
device for structural heart disease with high success rates
and low complication rates.
The Amplatzer Multi-Fenestrated Septal Occluder or
“cribriform occluder” is similar to the ASO device with the
exception of a narrow waist and equal sized atrial discs. This
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defects.
The Gore HSO was approved by the FDA in 2007 for
percutaneous ASD closure. The HSO is composed of an
expanded polytetrafluoroethylene membrane connected by a
single nitinol wire (Fig. 6). Once deployed, the HSO device
has a double disc shape that straddles the septal defect. The
nitinol wire frame forms a locking loop that secures the LA
and RA disks to each other, thus sealing the atrial defect.
The HSO device is available in diameters ranging from 15
to 35 mm, in 5-mm increments, and requires a 10-F
delivery sheath catheter. The HSO device can be reposi-
tioned if the locking loop has not been deployed. Once the
locking loop has been set, a retrieval cord is available for
device removal if necessary. The HSO is soft and flexible
and is well-tolerated but not self-centering and is preferable
for use in smaller ASDs.
Percutaneous ASD closure complications. Transcatheter
ASD closure is a safe procedure with a low complication
rate. Several reports reveal a 1.2% to 2.5% major complica-
tion rate and 3.4% to 6.1% minor complication rate (47–49).
Major complications include device embolization, erosion,
pericardial effusion with tamponade, device thrombus,
stroke, and endocarditis. Minor complications include ex-
cessive inflammatory reactions (perhaps due to nickel al-
lergy), cardiac arrhythmias, and femoral access site compli-
cations. The most serious and prevalent complications after
percutaneous ASD will be discussed.
ATRIAL ARRHYTHMIAS. The incidence of post-procedural
Figure 5 Amplatzer Septal Occluder
The Amplatzer Septal Occluder. Reprinted, with permission, from
St. Jude Medical, (Plymouth, Minnesota).trial fibrillation is 4.1%, which is higher than with PFOlosure (36). This increased incidence of atrial fibrillation in
SD closure might simply be part of the predisposition of
atients with ASD to develop atrial fibrillation. Alterna-
ively, a local inflammatory reaction might irritate the atria
utomaticity. Stretching the atrial septum with large devices
ight also predispose to arrhythmias. Atrial flutter/
brillation is an important cause of long-term morbidity
nd mortality in post-closure ASD patients for both surgical
nd percutaneous repair.
DEVICE EROSION. Although device erosion is a rare com-
plication of percutaneous ASD closure, there was a sharp
increase in this complication shortly after the FDA ap-
proved the ASO device in 2001. During the FDA trials,
devices were implanted that were, on average, 0.5 mm larger
than the stretched diameter of a sizing balloon, and there
were no reported cases of ASO device erosion. However,
post-marketing reports of device erosion sparked a physician
review panel that revealed that 68% of patients developed
symptoms within 72 h. Device perforation occurred in the
LA roof and aorta, RA roof and aorta, and both atria in 1
case (50). Of the 28 cases evaluated, 89% of patients had
either a deficient aortic rim and/or deficient superior rim. It
was the consensus that an oversized device was the most
likely cause of device erosion. Mechanistically, the oversized
device rubs against the atrial walls with each cardiac cycle,
leading to erosion through the area of contact. The recom-
mendation of this panel was to avoid oversizing by 2 mm
beyond the stretched atrial defect diameter (by balloon
sizing). After the implementation of this guideline, the
incidence of ASO device erosions has decreased.
DEVICE EMBOLIZATION. The reported rate of device em-
bolization ranges from 0.55% to 1.7% (51). Procedural
characteristics that increase the rate of device embolization
include smaller devices and insufficient septal rims. Embo-
Figure 6 Gore Helex Septal Occluder
The Gore Helex Septal Occluder (W. L. Gore &
Associates, Inc., Flagstaff, Arizona) and its delivery system.
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layed embolizations also occur. Most of these embolized
devices are retrievable by percutaneous techniques, which
have been described for the ASOs and Gore Helex devices
(51,52). Only a minority of embolized devices require
surgical removal or subsequent surgical closure of the ASD.
DEVICE THROMBOSIS. The incidence of thrombus forma-
tion on the device is low and device-dependent. Risk factors
for device thrombosis include post-procedure atrial fibrilla-
tion, persistent ASA, and coagulation disorders (53). The
incidence was approximately 1.2%, with the CardioSEAL/
STARflex having the highest rate (7.1%), whereas the
Amplatzer device had no thrombus formation (53). Clinical
studies of the Amplatzer and Gore Helex devices reveal an
incidence of thrombus formation of 0.2% and 0.8%, respec-
tively (13,53). The treatment for device thrombosis is
anticoagulation; however, there is a risk of stroke when the
thrombus is on the LA side, and surgical treatment might
be required for large, mobile thrombus.
Conclusions
There have been impressive advances over the past 20 years
in the field of percutaneous repair of atrial defects. Percu-
taneous ASD closure is relatively safe, reduces clinical
sequelae associated with ASD, and has become the pre-
ferred method for treatment of secundum ASDs. Percuta-
neous PFO closure is also a safe procedure that is performed
on an “off label” basis. There are strong observational data to
suggest benefit from PFO closure in conditions such as
cryptogenic stroke, migraine headache with aura, decom-
pression illness, and platypnea-orthodeoxia syndrome. The
recent randomized trial data on PFO closure for migraine
and cryptogenic stroke have contradicted the observational
reports, but these results might be due to the particular
device that was used, which no longer is being produced.
The results of the current randomized trials for secondary
stroke prevention and treatment of severe disabling mi-
graine are eagerly awaited and might clarify the role of
percutaneous PFO closure.
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